Objective: Abnormalities in the regulation of natriuretic peptides (NP) associated with major diseases such as hypertension, heart failure, and diabetes mellitus (DM) have been reported. We investigated levels of mRNA for the vasodilator C-type natriuretic peptide (CNP) in the renal cortex of streptozotocin (STZ)-diabetic rats and the influence of an angiotensin II inhibition. Methods: DM was induced in Wistar rats by a single STZ injection. Rats were kept for 12 weeks. Additionally, the influence of the ACE inhibitor ramipril (Ram: 3 mg / kg / day) and the AT1 receptor antagonist losartan (Los: 20 mg / kg / day) on CNP expression in the STZ-diabetic and control groups was studied (each group n56). Animals were characterized by their mean arterial blood pressure, plasma glucose levels, and renal function (each group n59). After extraction of total renal cortical RNA, CNP expression was analyzed by Northern blots. Results: Renal function was impaired in STZ-diabetic rats which has been improved by Ram and Los treatment. Untreated STZ-diabetic rats showed no difference in renal CNP expression compared to untreated controls. Ram and Los treatments led to an increase in renal cortical CNP mRNA in both diabetic and non-diabetic rats. This effect was weaker in STZ-diabetic rats (Ram: control 5.4-fold, STZ 3.5-fold; Los: control 4.2-fold, STZ 1.9-fold). Conclusion: These results clearly demonstrate a direct regulatory effect of the renin-angiotensin system (RAS) on renal mRNA levels of CNP. We suggest that RAS inhibition not only prevents the generation of angiotensin II (AngII) but also leads to a stimulation of CNP expression. We conclude that AngII suppresses CNP expression via the AT1 receptor and this mechanism is impaired in STZ-diabetic rats.
Introduction
shear stress [2] and septic shock [3] . CNP itself is discussed as an endothelium-derived vasodilator [3] , a C-type natriuretic peptide (CNP) is a 22-amino acid selective cardiovascular peptide [4] , a growth inhibitor of peptide that shows a high structural homology to the two vascular smooth muscle cells [5] , and a modulator of other members of the natriuretic peptide family, atrial ACTH-induced aldosterone secretion [6] . First identified in (ANP) and brain (BNP) natriuretic peptide. Whereas ANP the porcine brain [7] , CNP expression could be also and BNP are secreted in an endocrine fashion mainly from detected in the human endothelium [8] and kidney, includthe heart and are ligands for the natriuretic peptide receptor ing glomeruli and renal vasculature as well as walls of A (GC-A), a guanylyl-cyclase-coupled receptor on the cell large extrarenal vessels [6] . The biological role of CNP in membrane, C-type natriuretic peptide acts predominantly the kidney is not fully understood, but the existence of a in an autocrine / paracrine fashion and binds specifically to glomerular CNP system that may regulate tissue homeostathe natriuretic peptide receptor B (GC-B) [1] .
sis and control mesangial cell proliferation has been It was shown that CNP-precursor release is triggered by proposed [9] . Little is known about the renal pathophysiological function of CNP. In experimental renal mesangioprolifera- tive syndromes, CNP treatment led to renal protective mg / kg) after implanting femoral arterial and venous effects including inhibition of mesangial cell proliferation catheters [10]). Finally, mean arterial pressure (MAP) was and matrix accumulation [9] . Since nothing was known measured in the conscious state via the arterial catheter about CNP regulation in diabetic nephropathy, which is (each group n59), as previously described [11] . At the end also accompanied by mesangial cell proliferation, we of the study (12th week), these rats were placed in investigated the renal cortical expression of CNP in metabolic cages and urine was collected for 24 h to streptozotocin (STZ)-diabetic rats for 12 weeks and in a measure total protein excretion using the pyrogallol red control group of non-diabetic rats. At present, STZ treatmethod (Analyticon, Germany). ment currently provides the best characterized model for type I diabetes mellitus (DM) in rats. Additionally, CNP 2.2. CNP detection expression under either an angiotensin-converting enzyme inhibitor (ACEI) or an AT1 receptor antagonist was
To determine renal cortical RNA expression, six anaesinvestigated in both groups to clarify the renal interaction thetized rats of groups A-F were exsanguinated and the between the renin-angiotensin system (RAS) and CNP.
kidneys excised. Renal cortices were macroscopically separated from renal medullae and rapidly frozen in liquid nitrogen.
Methods
Northern blot analysis of renal cortices was performed after homogenisation and total RNA extraction using the 2. All data ate expressed as means6S.E.M. Data were the single-shot STZ injection providing the best characteranalysed using a two-way analysis of variance (ANOVA) ized model for type I DM model in rats.
in conjunction with Student's t-test. P values ,0.05 were Hyperglycemia was confirmed 48 h later by a reflectaccepted as significant. ance meter (Acutrend, Boehringer Mannheim, Germany). Non-diabetic rats were used as controls (A), treated with Ram (ACEI; 3 mg / kg / day per gavage) (B), or treated with 3. Results Los (AT1 receptor antagonist; 20 mg / kg / day per gavage) (C). In a pilot experiment, these doses have been demon-3.1. Characteristics of diabetic rats strated to inhibit 90% of the vasopressor effect of exogenous AngI (Ram) or AngII (Los).
As summarised in Table 1 , all groups of STZ-diabetic The STZ-diabetic rats were randomized to receive one rats developed severe hyperglycaemia after 12 weeks. The of the following three regimens for a period of 12 weeks:
increase was significant compared to controls (P,0.01). no treatment (D), Ram (E), or Los (F). This time span was MAP did not differ significantly between treated and chosen because rats are known to develop severe diabetic untreated non-diabetic rats, and STZ-diabetic rats. Diabetic nephropathy accompanied by increased glomerular basal rats treated with Ram or Los showed no significant membrane thickness, mesangial cell proliferation and changes in MAP compared to controls (Table 1) . glomerular matrix accumulation 12 weeks after STZ All treatment groups of STZ-diabetic rats showed injection [12] . Throughout the 12-week study period, STZsimilar blood glucose and MAP values. However, GFR treated rats (n515 per group) displayed severe hyand renal protein excretion levels differed. Although all perglycaemia (.600 mg / dl).
groups of STZ diabetic rats showed a marked GFR After the 11th week, glomerular filtration rate (GFR) reduction and an increase in urinary protein excretion was measured by a single inulin injection method (800 compared to non-diabetic animals, Ram-or Los-treated STZ-diabetic rats had an improved GFR (P,0.05) and a contrast to renal ANP [14] , the development of diabetic reduced urinary protein excretion compared to untreated nephropathy, which is characterised by increased glomeru-STZ-diabetic rats (P,0.01).
lar pressure and mesangial cell proliferation does not influence CNP gene expression after 12 weeks, although 3.2. CNP expression the peptide is a vasodilator and antiproliferative agent [9] . Additionally, under diabetic conditions, renal CNP CNP expression was analysed by Northern blot analysis mRNA is regulated differently from cardiac CNP gene (Fig. 1) . RNA was detectable for all samples using the expression, which we recently found to be downregulated b-actin probe (Fig. 1A) . In untreated STZ-diabetic rats no in diabetic cardiopathy [15] . difference in renal cortical CNP expression was found Moreover, an inhibition of the RAS in control and compared to controls. Additionally, we studied in both diabetic rats led to a significant increase of CNP exprescontrol and STZ-diabetic rats the influence of Ram and sion. The weaker increase in CNP mRNA in STZ-diabetic Los on CNP expression (each group n56). Both treatments rats compared to controls after RAS inhibition may led to an increase of renal cortical CNP mRNA in all indicate diabetic-induced interstitial changes including cell experimental groups (Fig. 1B) . The CNP-mRNA levels atrophy and fibrosis. However, since an up regulation of were more pronounced after ACEI than after AT1 receptor CNP mRNA by AT1 blockade is a direct proof for CNP blockade, though this effect was weaker in STZ-diabetic mRNA suppression by A II, we are the first to demonstrate than in control kidneys (Ram: control 5.4-fold, STZ 3.5-that AngII down regulates renal CNP expression under fold; Los: control 4.2-fold, STZ 1.9-fold).
physiological and diabetic conditions. Since CNP expression was more pronounced under ACEI treatment than under AT1 receptor blockade, either 4. Discussion ACE itself triggers CNP mRNA to a small degree via angiotensin-independent pathways, or the angiotensin-reThe aim of the study was to investigate renal cortical ceptor AT2 is also involved in the regulation of CNP CNP mRNA in STZ-diabetic rats compared to controls and expression. In addition, since plasma concentrations of the influence of an ACEI or an AT1 receptor antagonist on CNP were not significantly affected by AngII infusion CNP expression under diabetic and control conditions.
[16], whereas a renal RAS blockade in our study led to Since plasma, renal and urinary CNP peptide concenaugmented CNP-mRNA concentrations in kidney, our trations are influenced by glomerular hypofiltration and findings give a new indication of an autocrine function of proteinuria in our DM type I rat model, the detection of CNP. One further indication that CNP is involved in the renal cortical CNP mRNA is a more specific marker of beneficial effects of angiotensin inhibition using ACEI or CNP regulation than measurement of peptide concentraan AT1 antagonist is the inhibitory effect of AngII on the tions.
growth arrest-specific homeobox (Gax) gene, a factor Our results are the first to demonstrate that renal CNPinvolved in the suppression of neointima formation, wheremRNA levels in STZ-diabetic rats with reduced GFR and as CNP up regulates Gax mRNA [17] . In addition, Segawa glomerular damage indicated by increased urinary protein et al. [18] found that CNP inhibits rat mesangial cell levels, do not differ from those in to controls with normal proliferation. This is in agreement with studies of Canaanrenal function 12 weeks after STZ injection. Since Shin et Kuhl et al. [9] , showing that CNP treatment inhibits al. [13] found renal upregulation of CNP mRNA 8 weeks mesangial cell proliferation and matrix accumulation in a after STZ injection, more severe nephropathy [12] 12 rat model of mesangioproliferative glomerulonephritis in weeks after the induction of experimental diabetes enables vivo. Therefore, an up regulation of the renal CNP axis the kidney to upregulate CNP gene expression. Thus, in may also lead to a reduction of renal hypertrophy and mesangial proliferation under diabetic conditions. CNP peptide level, since Davidson et al. [20] could show that seems not to be an inhibitor of the physiological actions of CNP is an endogenous inhibitor of vascular ACE activity. AngII, such as pulmonary pressor effects and stimulation Therefore, CNP stimulation may lead to an additional of aldosterone secretion [19] , but an inhibitor of the AngII down regulation of the RAS after an initial blockade of the
